Treatment
Empagliflozin clinical trials
We’re tracking 87 recruiting studies that include Empagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT04670666RecruitingPhase 3
Study of Madalena for type 2 diabetes not controlled
This Phase 3 study tests Madalena to improve blood sugar control in adults with type 2 diabetes that hasn’t met targets despite diet, exercise, and diabetes medicines. You may join if your recent blood sugar tests and body size fall within specific ranges and you don’t have key medical exclusions.
Hortolândia, São PauloAges 18 years+ - NCT05028140RecruitingPhase 3
Testing a lifestyle-and-diet program for type 2 diabetes control
This Phase 3 study tests whether a program run by the Piemonte Association can improve blood sugar control in people with type 2 diabetes who haven’t reached their target after usual diet, exercise, and stable medicines. It also aims to check that the approach is safe for participants.
Hortolândia, São PauloAges 18–85 - NCT05164263RecruitingPhase 4
Testing empagliflozin for adults with type 2 diabetes on tablets
This study looks at how well and how safely empagliflozin works in real-world care for adults with type 2 diabetes who are not controlled on current pill treatment. Some participants take it with metformin, and the study helps confirm what to expect in everyday patients.
Kabul, AfghanistanAges 18–65 - NCT05610956RecruitingEarly Phase 1
Empagliflozin for mild-to-moderate ulcerative colitis
This early trial studies whether empagliflozin can improve ulcerative colitis symptoms and is safe for people with mild to moderate disease. If it works, it may reduce ongoing colon inflammation and help people feel better.
TantaAges 18–70 - NCT05726032RecruitingPhase 2
Empagliflozin for fluid buildup from cirrhosis
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
New Haven, ConnecticutAges 18 years+ - NCT05786443RecruitingPhase 2
Empagliflozin test in adults on regular dialysis
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Boston, MassachusettsAges 18 years+ - NCT05879276RecruitingPhase 3
Early empagliflozin for shock patients after ICU start
This trial studies whether starting empagliflozin early in adults with cardiogenic shock helps people live longer and have fewer hospital returns, while also checking heart pumping and kidney function. It may help some ICU patients, but eligibility is strict and depends on kidney function and prior medication use.
Ars-LaquenexyAges 18 years+ - NCT05905965RecruitingPhase 3
Higher versus standard empagliflozin dose for metabolic syndrome
This trial tests whether a higher dose of empagliflozin works better than the standard dose to treat metabolic syndrome. It may help improve blood sugar and cholesterol-related risk factors in people who meet the trial’s criteria.
Bydgoszcz, Cuiavian-PomeranianAges 18–85 - NCT06013865RecruitingPhase 4
Empagliflozin for kidney transplant recipients
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
Hines, IllinoisAges 19 years+ - NCT06021145RecruitingPhase 4
Adding empagliflozin to insulin pumps for type 1 diabetes
This study tests whether adding the diabetes pill empagliflozin (Jardiance) to your current automated insulin pump can help improve blood sugar control for adults with type 1 diabetes who are not reaching their glucose goals.
Montreal, QuebecAges 18 years+ - NCT06095492Recruiting
Comparing diabetes drugs after kidney transplant
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
Gurgaon, HaryanaAges 30 years+ - NCT06110130RecruitingPhase 4
Empagliflozin for kidney health in African American veterans
This study is testing whether the drug empagliflozin (Jardiance) can help protect the kidneys of African American veterans who already have some kidney damage but do not have diabetes. The goal is to see if the drug can reduce damage at the cellular level.
Washington D.C., District of ColumbiaAges 19–90 - NCT06249932RecruitingPhase 4
Empagliflozin for heart failure and end-stage kidney disease
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
Hsinchu, TaiwanAges 20 years+ - NCT06249945RecruitingPhase 4
Empagliflozin for heart failure with preserved ejection fraction and dialysis
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
HsinchuAges 20 years+ - NCT06424288RecruitingPhase 3
Testing vicadrostat plus empagliflozin for heart failure
This study tests whether adding a new study drug called vicadrostat to the standard heart failure medicine empagliflozin helps people with heart failure. It may be a good option if you have heart failure with preserved pumping function and are not already on a medicine called an MRA.
Mobile, AlabamaAges 18 years+ - NCT07692256RecruitingPhase 2
Empagliflozin for heart failure in children
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
Cairo, Cairo GovernorateAges 1 month–18 years - NCT06507657RecruitingEarly Phase 1
Empagliflozin for heart health in older adults
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Minneapolis, MinnesotaAges 60 years+ - NCT06554301RecruitingPhase 1
Empagliflozin for pulmonary arterial hypertension study
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06578676RecruitingPhase 1
Testing two new drugs in healthy adults
This trial tests how two new drugs (HODO-22251 and HODO-22252) interact with each other and how safe they are in healthy adults. It helps doctors understand the best way to give these drugs together.
Daegu, Gyeongsangbuk-doAges 19 years+ - NCT06642272RecruitingPhase 4
Comparing two diabetes drugs in real-world use
This trial compares two common diabetes medications, empagliflozin and dapagliflozin, to see which works better in everyday practice. It aims to find the best treatment option for patients with type 2 diabetes.
CopenhagenAges 18 years+ - NCT06653738RecruitingPhase 3
Testing empagliflozin and diet advice for kidney stone prevention
This trial tests if a medication called empagliflozin, combined with personalized diet advice, can help prevent kidney stones from coming back. It may be an option if you've had two or more kidney stone events in the last 10 years and your stones were mostly calcium-based.
AmiensAges 18 years+ - NCT06762314RecruitingPhase 2
Empagliflozin or semaglutide for overweight people with type 1 diabetes
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
TantaAges 18–65 - NCT06862739RecruitingPhase 4
Testing a 3-drug combination for better blood sugar control
This study tests a combination of three diabetes medicines (empagliflozin, linagliptin, and metformin) to see if it helps control blood sugar in people with type 2 diabetes. It may be an option if your current treatment isn't working well enough.
Faisalabad, Punjab ProvinceAges 18–80 - NCT07093476RecruitingPhase 3
Adding empagliflozin to improve blood sugar control
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
SeoulAges 19 years+
Common questions
- Are there clinical trials studying Empagliflozin?
- Yes. Clin2 currently lists 87 recruiting studies that include Empagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Empagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Empagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Empagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.